US 5595756A
· Bally et al.
· 1997
[cited by applicant]
US 6416973B1
· Bakker et al.
· 2002
[cited by applicant]
US 6953843B2
· Bakker et al.
· 2005
[cited by applicant]
US 7332574B2
· Bakker et al.
· 2008
[cited by applicant]
US 8034771B2
· Sims et al.
· 2011
[cited by applicant]
US 8481021B2
· Sims et al.
· 2013
[cited by applicant]
US 9023995B2
· Brown
· 2015
[cited by examiner]
US 9334320B2
· Okun et al.
· 2016
[cited by applicant]
US 20040110930A1
· Reinl et al.
· 2004
[cited by applicant]
US 20070041905A1
· Hoffman et al.
· 2007
[cited by applicant]
US 20080171035A1
· Bakker et al.
· 2008
[cited by applicant]
US 20090263403A1
· Bakker et al.
· 2009
[cited by applicant]
US 20100129374A1
· Bakker et al.
· 2010
[cited by applicant]
US 20100221252A1
· Bigler et al.
· 2010
[cited by applicant]
US 20110110852A1
· Miller et al.
· 2011
[cited by applicant]
US 20110159011A1
· Carrier et al.
· 2011
[cited by applicant]
US 20120121580A1
· Bhambhani et al.
· 2012
[cited by applicant]
US 20120177647A1
· Bigler et al.
· 2012
[cited by applicant]
US 20120244158A1
· Brige et al.
· 2012
[cited by applicant]
US 20180273627A1
· Boecher et al.
· 2018
[cited by applicant]
US 20190028285A1
· Cheng
· 2019
[cited by applicant]
US 20190284273A1
· Boecher et al.
· 2019
[cited by applicant]
US 20190284285A1
· Thoma et al.
· 2019
[cited by applicant]
US 20200207862A1
· Baum et al.
· 2020
[cited by applicant]
US 20220119538A1
· Thoma et al.
· 2022
[cited by applicant]
US 20220402998A1
· Liu et al.
· 2022
[cited by applicant]
CN 107362351A
· 2017
[cited by applicant]
EP 1003861A2
· 2000
[cited by applicant]
EP 1627927A2
· 2006
[cited by applicant]
EP 2152750A1
· 2010
[cited by applicant]
EP 2176294A1
· 2010
[cited by applicant]
EP 2337799A2
· 2011
[cited by applicant]
JP 2009521933A
· 2009
[cited by applicant]
JP 2016531123A
· 2016
[cited by applicant]
JP 2017114829A
· 2017
[cited by applicant]
JP 2018512157A
· 2018
[cited by applicant]
JP 2020512344A
· 2020
[cited by applicant]
KR 20180098625A
· 2018
[cited by applicant]
WO 9856418A1
· 1998
[cited by applicant]
WO 9906557A2
· 1999
[cited by applicant]
WO 9906577A2
· 1999
[cited by applicant]
WO 2004091658A1
· 2004
[cited by applicant]
WO 2008033333A2
· 2008
[cited by applicant]
WO 2008133857A1
· 2008
[cited by applicant]
WO 2009006112A1
· 2009
[cited by applicant]
WO 2010025369A2
· 2010
[cited by applicant]
WO 2013074569A1
· 2013
[cited by applicant]
WO 201616842A1
· 2016
[cited by applicant]
WO 16168542A1
· 2016
[cited by applicant]
WO 2016168542A1
· 2016
[cited by applicant]
WO 2017117311A1
· 2017
[cited by applicant]
WO 2018183173A1
· 2018
[cited by applicant]
WO 2019177883A2
· 2019
[cited by applicant]
WO 2019177888A1
· 2019
[cited by applicant]
WO 2020136101A1
· 2020
[cited by applicant]
WO 2020185479A1
· 2020
[cited by applicant]
Ly et al, Psoriasis: Targets and Therapy 2019:9 37-42 37 (Year: 2019).
[cited by examiner]
Vajdos et al. (J Mol Biol. Jul. 5, 2002;320(2):415-28 (Year: 2002).
[cited by examiner]
Brown et al. (J Immunol. May 1996;156(9):3285-91 (Year: 1996).
[cited by examiner]
Waiker et al (J Am Soc Nephrol. Jan. 2012; 23(1): 13-21) (Year: 2012).
[cited by examiner]
Mayeux (NeuroRx. Apr. 2004;1(2):182-8) (Year: 2004).
[cited by examiner]
Neuhauser et al, Experimental Dermatology. 2020;29:1088-1096 (Year: 2020).
[cited by examiner]
Aydin et al (Clinical, Cosmetic and Investigational Dermatology 2020:13 611-625) (Year: 2020).
[cited by examiner]
Johnston et al (J Allergy Clin Immunol. Jul. 2017 ; 140(1): 109-120) (Year: 2017).
[cited by examiner]
Aagaard, Lars et al. “RNAi therapeutics: Principles, prospects and challenges” (2007) Advanced Drug Delivery Reviews, vol. 59, 75-86.
[cited by applicant]
Arend, William P. et al. “IL-1, IL-18, and IL-33 families of cytokines” Immunological Reviews (2008) vol. 223, pp. 20-22.
[cited by applicant]
Blumberg, Hal et al. “IL-1RL2 and Its Ligands Contribute to the Cytokine Network in Psoriasis” The Journal of Immunology (2010) vol. 185, pp. 4354-4362.
[cited by applicant]
Blumberg, Hal et al. “Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation” The Journal of Experimental Medicine (2007) vol. 204, No. 11, pp. 2603-2614.
[cited by applicant]
Born, Teresa et al. “Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation of a new class of IL-1R-related proteins based on signaling” The Journal…
[cited by applicant]
Bowie, James U. et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” Science (1990) vol. 247, pp. 1306-1310.
[cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2”, J. Immunol., 1996, 156, pp. 3285-3291.
[cited by applicant]
Burgess, Wilson H. et al. “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis o…
[cited by applicant]
Chustz, Regina T. et al. “Regulation and Function of the IL-1 Family Cytokine IL-1F9 in Human Bronchial Epithelial Cells” Am J Respir Cell Mol Biol (2011) vol. 45, pp. 145-153.
[cited by applicant]
Clark, James D. et al. “Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases” (2014) American Chemical Society, 5023-5038.
[cited by applicant]
Clinical Trials “A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis (PPP)” NCT03633396, (2019) clinicaltrails.gov, 8 pgs.
[cited by applicant]
Clinical Trials “History of Changes for Study: NCT03135548, Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients” (2020) clinicaltrials.gov, 5 pgs.
[cited by applicant]
Clinical Trials “History of Changes for Study: NCT03782792, A Study to Test BI 655130 in Patients iwth Flare-up of a Skin Disease called Generalized Pustular Psorasis” (2018) clinicaltrials.gov, 6 pgs.
[cited by applicant]
Creative Diagnostics “Mouse anti-IL1RL2 Monoclonal Antibody” Product Information. Gene ID 8808. mRNA Ref Seq NM_003854. (2004).
[cited by applicant]
Debets, Reno et al. “Two Novel IL-1 Family Members, IL-1d and IL-le Function as an Antagonist and Agonist of NF-kb Activation Through the Orphan IL-1 Receptor-Related Protein 21” The Journal of Immunology (2001) vol. 16…
[cited by applicant]
Dinarello, Charles A. “Immunological and Inflammatory Functions of the Interleukin-1 Family” The Annual Review of Immunology (2009) vol. 27, pp. 519-550.
[cited by applicant]
Dinarello, Charles et al. “IL-1 family nomenclature” Nature Immunology (2010) vol. 11, pp. 973-974.
[cited by applicant]
Guido, Rafael V.C. et al. “Virtual Screening and Its Integration with Modern Drug Design Technologies” (2008) Current Medicinal Chemistry, vol. 15, 37-46.
[cited by applicant]
International Search Report for PCT/US2012/064933 filed Nov. 14, 2012, mailed Feb. 7, 2013.
[cited by applicant]
International Search Report for PCT/US2019/021296 mailed Feb. 27, 2020.
[cited by applicant]
International Search Report PCT/EP2019/086521 mailed Apr. 6, 2020.
[cited by applicant]
International Search Report PCT/US2018/024296 mailed Jun. 22, 2018.
[cited by applicant]
Johnston, Andrew et al. “IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System that is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression” The Journal of Immunology (2011) vol. 186,…
[cited by applicant]
Lazar, Eliane et al. “Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities” Molecular and Cellular Biology (1988) vol. 8, No. 3, pp. 1247-1252.
[cited by applicant]
Lingel, Andreas et al. “Structure of IL-33 and its Interaction with the ST2 and IL-1RAcP Receptors—Insight into Heterotrimeric IL-1 Signaling Complexes” Structure (2009) vol. 17, pp. 1398-1410.
[cited by applicant]
Lovenberg, Timothy W. et al. “Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL1R-rp2)” Journal of Neuroimmunology, (1996) vol. 70, pp. 113-122.
[cited by applicant]
Magne, David et al. “The new IL-1 Family Member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes” Arthritis Research & Therapy (2006) vol. 8:R80, 11 pgs.
[cited by applicant]
Marrakchi, Slaheddine et al. “Interleukin-36-Receptor Antagonist Deficiency and Generalized Pustular Psoriasis” New England Journal of Medicine (2011) vol. 365 pp. 620-628.
[cited by applicant]
Matsuba et al., “Preparation of Super-High Affinity Rabbit Monoclonal Antibodies Against Estradiol.: Application to Highly Sensitive Estradiol Measurement”, TOSOH Research & Technol. Review. 2008, vol. 52, pp. 3-9.
[cited by applicant]
Mckeaugue, Maureen et al. “Challenges and Opportunities for Small Molecule Aptamer Development” (2012) Journal of Nucleic Acids, Article ID: 748913, 20 pgs.
[cited by applicant]
Mcmahan, Catherine J. et al. “A Novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types” EMBO Journal (1991) vol. 10, No. 10, pp. 2821-2832.
[cited by applicant]
NCBI Gene databases (IL1RL2 interleukin 1 receptor-like 2 [
[cited by applicant]
Qin, Jian-Zhong et al. “Role of NF-kB in the Apoptotic-resistant Phenotype of Keratinocytes” (1999) vol. 274, No. 53, 37957-37964.
[cited by applicant]
Ramadas, Ravisankar A. et al. “IL-36a Exerts Pro-Inflammatory Effects in the Lungs of Mice” PLOS one (2012) vol. 7, Issue 9, e45784, 17 pgs.
[cited by applicant]
Ramadas, Ravisankar A. et al. “Interleukin-1 Family Member 9 Stimulates Chemokine Production and Neutrophil Influx in Mouse Lungs” Am J Respir Cell Mol Biol (2011) vol. 44, pp. 134-145.
[cited by applicant]
Scheibe, Kristina et al. “Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice with Chronic Intestinal Inflammation” (2019) Gastroenterology, vol. 156, No. 4, 1082-1097.
[cited by applicant]
Steidl et al., “In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification”, Mol. Immunol, 2008, vol. 46, pp. 135-144.
[cited by applicant]
Su, Zhi et al. “IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis” (2019) Experimental Dermatology, 28, 113-120.
[cited by applicant]
Tortola, Luigi et al. “Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk” The Journal of Clinical Investigation (2012) vol. 122, No. 11, pp. 3965-3976.
[cited by applicant]
Towne, Jennifer E. et al. “Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-kB and MAPKs*” The Journal of Biological Chemistry (2004) vol. 279, No. 14, …
[cited by applicant]
Towne, Jennifer E. et al. “Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36a, IL-36b, and IL-36g) or Antagonist (IL-36Ra) Activity” The Journal of Biological Chemistry (2011) vol. 286, No. 49, p…
[cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigenbinding Site of an Anti-Erb82 Antibody Obtained with Shotgun Scanning Mutagenesis”, J. Mol. Biol., 2002, 320, pp. 415-428.
[cited by applicant]
Warzocha, Krzysztof et al. “Antisense Strategy: Biological Utility and Prospects in the Treatment of Hematological Malignancies” (1997) Leukemia and Lymphoma, vol. 24, 267-281.
[cited by applicant]
Clinical Trials “BI655130 Single Dose in Generalized Pustular Psoriasis” (2018) Identifier: NCT02978690, 6 pgs.
[cited by applicant]
Clinical Trials “This Study Tests How BI 655130 Works in Patients with Active Ulcerative Colitis. The Study also Tests how well BI 655130 is Tolerated and Whether it Helps the Patients” (2020) NCT03100864, 28 pgs.
[cited by applicant]
Russell, Se et al. “IL-36a expression is elevated in ulcerative colitis and promotes colonic inflammation” (2016) Mucosal Immunology, vol. 9, No. 5, 1193-1204.
[cited by applicant]
Ding, Liping et al. “IL-36 cytokines in autoimmunity and inflammatory disease” (2018) Oncotarget, vol. 9, No. 2, 2895-2901.
[cited by applicant]
Nishida, Atsushi et al. “Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease” (2016) Inflamm Bowel Dis, vol. 22, No. 2, 303-314.
[cited by applicant]
Andoh, Akira et al. “Increased Expression of Interleukin-36 in the Inflamed Mucosa of Inflammatory Bowel Disease” Abstract 1812, (2015) The American Journal of Gastroenterology, vol. 110, Supplement 1, S770.
[cited by applicant]
Johnston, Andrew et al. “IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis” (2017) J Allergy Clin Immunol, 109-120.
[cited by applicant]
Tsai, Ya-Chu et al. “Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness” (2017) Therapeutic Advances in Musculoskeletal Disease, vol. 9 (11), 277-294.
[cited by applicant]
Body Mass Index Table from www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_tbl.pdf <http://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_tbl.pdf>, viewed Sep. 16, 2021.
[cited by applicant]
Wong, Chi Heem et al. “Estimation of clinical trial success rates and related parameters” (2019) Biostatistics, 20, 2, 273-286.
[cited by applicant]
Clinical Trials “A Study in Patients with Atopic Eczema to Test How Effective BI 655130 Is and How Well It Is Tolerated” (2021) Last Update Posted, NCT03822832, 11 pgs.
[cited by applicant]
Wang, Wei et al. “Antibody Structure, Instability and Formulation” (2007) Journal of Pharmaceutical Sciences, vol. 96, No. 1, 1-26.
[cited by applicant]
Boehringer Ingelheim “Boehringer Ingelheim R&D pushes to Transcend Disease Boundaries” (2018) Business Wire, 4 pgs.
[cited by applicant]
Lacy, et al. “Correlation between Antibody Affinity and Activity: Understanding the Molecular Basis for a Picomolar to Femtomolar Increase in Affinity” (2009) Abstract, 1621-Pos, Board B465, vol. 96, Issue 3, S1, 317a-3…
[cited by applicant]
Bachelez, Herve et al. “Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis” (2019) The New England Journal of Medicine, 380: 10, 981-983.
[cited by applicant]
Satoh T K et al: “Are neutrophilic dermatoses autoinflammatory disorders?” (2018) The British Journal of Dermatology, vol. 178, No. 3, pp. 603-613.
[cited by applicant]
Marzano Angelo V. et al: “Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases”, (2019) Frontiers in Immunology, vol. 18, 2019, p. 1859.
[cited by applicant]
Mrowietz Ulrich et al: “Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study”, (20…
[cited by applicant]
International Search Report PCT/US2021/041734 mailed Nov. 11, 2021, 4 pgs.
[cited by applicant]
Clinical Trials, Interleukin-1 receptor-like 2 isoform a precursor, downloaded from https://ncbi.nlm.nlh.gov/protein/NP_003845.2?report+girevhist on Sep. 21, 2022 2022.
[cited by applicant]
Elias, IL-36 in chronic inflammation and fibrosis, JCI, vol. 131, 2021, 14 pages.
[cited by applicant]
Melton, Interleukin-36 Cytokine/Receptor Signaling, Int. J. of Molecular Sci., vol. 21, 2020, 22 pages.
[cited by applicant]
Neufert, Rationale for IL-36 receptor antibodies in ulcertaive colitis, Expert opinion on Biological Therapy, vol. 20, 2020, 5 pages, https://doi.org/10.1080.14712598.2020.1695775.
[cited by applicant]
Scheibe, Inhibiting Interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation, Gastroenterology, vol. 156, 2019, 27 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT.US2022/074888 mailed Nov. 29, 2022.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/019743 mailed Oct. 21, 2022.
[cited by applicant]
Baliwag, Cytokines in psoriasis, Cytokine, vol. 73, 2015, 9 pages.
[cited by applicant]
Baum, Generalized Pustular psoriasis and palmoplantar pustulosis both slow upregulation of the IL-36, neutrophil chemokine, and innate pathways that are modulated by spesolimab, and anti-IL-36 receptor antibody treatmen…
[cited by applicant]
Baum, Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, ESDR 2019 Annual Meeting, Retrieved from Internet: URL:https://www.sciencedirect.com/science/ar…
[cited by applicant]
Baum, Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis, Journal of Allergy and clinical immunology, vol. 149. 2021, p. 1402-1412.
[cited by applicant]
Brenner, Gernalized pustular psoriasis induced by systemic glucocorticosteroids, Bristish Journal of Dermatology, vol. 161, 2009, p. 964-963.
[cited by applicant]
Yuan, Biology of IL-36 Signaling and its role in systemic Inflammatory Diseases, Frontiers in Immunology, vol. 10, 2019, p. 2532.
[cited by applicant]
Zeng, Integrated analysis of gene expression profiles identifies transciption factors potentially involved in psoriasis pathogenesis, J. of Cellular Biochem., vol. 120, 2019, p. 12582-12594.
[cited by applicant]
Tortola, Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk, The J. of Clinical Investigation, vol. 122, 2012, p. 3965-3976.
[cited by applicant]
Foster, IL-36 promotes myeloid cell infiltration activation and inflammatory activity in skin, The j. of immunolgy, vol. 192, 2014, p. 6053-6061.
[cited by applicant]
Swindell, 7th International Congress of psoriais: from gene to clinic: The Queen Elizabeth II Conference Centre, London, UK, Dec. 11-13, 2014, British Journal of Dermatology, vol. 171, 2014, 69 pages.
[cited by applicant]
Creative Diagnostics “Mouse anti-IL 1RL2 Monoclonal Antibody” Product Information. Gene ID 8808. mRNA Ref Seq NM_003854. (2004) 1 page.
[cited by applicant]
Nolan, S. et al. “505 Therapeutic activity of an anti-IL36R blocking antibody in inhibiting atopic dermatitis-like skin inflammation in mice” (2019) Journal of Investigative Dermatology, Society for Investigative Dermat…
[cited by applicant]
Patrick, Garrett et al. “Epicutaneous
[cited by applicant]
Puar, Neha et al. “New treatments in atopic dermatitis” (2020) Annals Allergy Asthma Immunology, 126, 21-21.
[cited by applicant]
International Search Report PCT/US2021/032713 mailed Aug. 30, 2021, 12 pgs.
[cited by applicant]
International Search Report PCT/US2020/021059 mailed on Jun. 23, 2020.
[cited by applicant]
Anonymous Anti-IL36 gamma/IL-1 F9 antibody (OT12F4) (ab156783), Jan. 1, 2019, XP055650144, 6 pgs.
[cited by applicant]
Chang, Byeong S. et al. “Practical Approaches to Protein Formulation Development” (2022) Kluwer Academic/Plemum publishers, 1-25.
[cited by applicant]
Kang, Rapid Formulation Development for Monoclonal Antibodies, BioProcess Chem., vol. 14, 2016, 4 pages.
[cited by applicant]
Li, Spinal II-36/11-36R participates in the maintenance of chronic inflammatory pain through adtroglial JNK pathway, GLIA, vol. 67, 2019, Retrieved from the internet: URL: https://api.wiley.com/onlinelibrary.tdm/v1artic…
[cited by applicant]
Alvarez, Imiquimod Treatment causes systemic disease in mice resembling generalized pustular psoriasis in an IL-1 and IL-36 Dependent Manner, GLIA, vol. 1, 2016, Retrieved from the Internet, URL:http://downloads.hindawi…
[cited by applicant]
Ratnarajah, Spesolimab, a novel treatment for pustular psoriasis, Journal od cutaneous med and surgery, vol. 24, 2020, Retrieved from the internet, URL:http://jouranls.sagepub.com/doi/full-xml/10.1177/1203475419888862.
[cited by applicant]
Ganesan, Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies, MABS, vol. 9, 2017, p. 143-154.
[cited by applicant]
Kazumitsu, The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist, vol. 133, 2013, p. 514-521.
[cited by applicant]
A study to test how effective and safe different doses of BI 655130 are in patients with a moderate to severe form of the skin disease palmoplantar pustulosis. ClinicalTrials.gov identifier:NCT4015518. Jul. 9, 2019. Acc…
[cited by applicant]
Freitas, Screening and Treatment of Patients with palmoplantar Pustolosis (PPP): A review of current practices and recommendations. Clinical Cosmet. Invest. Dermatol., vol. 13, 2020, p. 561-578.
[cited by applicant]
Edwards, The remarkable flexibility of the human antibody repertoire, J, Mole. Biol., vol. 1, 2003, p. 103-118.
[cited by applicant]
Almagro, Humanization of antibodies, Front Biosci., vol. 13, 2008, p. 1619-33.
[cited by applicant]
Kussie, A single engineered amino acid substitution changes antibody fine specificity, J. Immunol., vol. 1, 1994, p. 146-152.
[cited by applicant]
Anonymous, A study in patients with atopic eczema to test how effective BI655130 is and how well it is tolerated, Retrieved from the internet, http:/clinicaltrials.gov.ct2/show/record/NCT3822832/retrieved Aug. 16, 2021.
[cited by applicant]
Melton, Interleukin-36 Cytokine/Receptor Signaling, Int. J. of Mol. Sci., vol. 21, 2020, 22 pages.
[cited by applicant]
Scheibe, Inhibiting Interleukin 36 Receptor Signaling reduces Fibrosis in mice with chronic intestinal inflammation, Gastrolenterology, vol. 156, 2019, 27 pages.
[cited by applicant]
Ring, The Follicular skin microbiome in patients with Hidradenitis Suppurativa and healthy controls, JAMA derma., vol. 153, 2017, 20 pages.
[cited by applicant]
Towne, Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RacP to activate the pathway leading to NF-KB and MAPKs*, The J. of Biological Chem, vol. 14, 2004, 12 pages.
[cited by applicant]
Sarkissian, Identification of Biomarkers and critical Eval. of Biomarker validation in Hidradentitis Suppurativa, JAMA Derma., vol. 158, 2022, 27 pages.
[cited by applicant]
Towne, Interleukin-36 (IL 36) ligands require processing for full agonist, J. of Biological Chemistry, vol. 286, 2011, 9 pages.
[cited by applicant]
Gao, Inversa acne a case report and ID of the locus at Chromosome 1p21.2-1q25.3, J. of investigative Derma., vol. 136, 2006, 5 pages.
[cited by applicant]
Dinarello, A clinical Perspective of IL-1B as the gatekeeper of inflammation, Euro. J. of Immunology, vol. 41, 2011, 15 pages.
[cited by applicant]
Webster, The Functional Assessment of Chronic Illness Therapy Measurement system, Bio Med Central, vol. 79, 2003, 7 pages.
[cited by applicant]
Di Caprio II-36 cytokines are increased in acne, Arch. Dermatol. Res., vol. 10, 2017, 6 pages.
[cited by applicant]
Van Straalen, Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross sectional dutch twin cohort, JAMA derma, vol. 156, 2020, 4 pages.
[cited by applicant]
Navrazhina, Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa, J. Allergy Clin. Immunol., vol. 12, 2020, 12 pages.
[cited by applicant]
Thomi, Increased expression of the interleukin-36 cytokines in lesions of hidradentitis suppurativa, JEADV, vol. 31, 2017, 6 pages.
[cited by applicant]
Jorgensen, Clinical, microbiological, immunological and imaging characteristics of tunnels and fistulas in hidradenitis suppurativa, Experimental Dermatology, vol. 29, 2019, 6 pages.
[cited by applicant]
Revillet, Bacterial pathogens associated with Hidradenitis Suppurativa, France, Emerginv infectious diseases, vol. 20, 2014, 9 pages.
[cited by applicant]
Winthrop, Opportunistic infections and biologic therapies in immune mediated inflammatory diseases, vol. 1, 2015, 12 pages.
[cited by applicant]
Bonnekoh, Spectrum of genetic autoinflammatory diseases presenting with cutaneous symptoms, Acta Derm Venereol., vol. 100, 2020, p. 140-151.
[cited by applicant]
Bai, Studies of mouse models of allergic disease, Chinese Journal of Comparative Medicine, vol. 2, 2020, 7 pages, Abstract only.
[cited by applicant]
Anon, Anaptybio Reports Harp Phase 2 top-line data of imsidolimab in moderate to severe hidradenitis suppurativa, Anaptysbio, 2016, 6 pages.
[cited by applicant]
Weiss, Neutrophilic Dermatoses, Current Dermatology Reports, vol. 11, 2022, 14 pages.
[cited by applicant]
Hunt, The current clinical trial landscape for hidradenitis suppurativa, vol. 13, 2023, 17 pages.
[cited by applicant]
Ferrante, Safety and tolerability of speso in patients with ulcertaive colitis, Exp. Opinion on drug safety, vol. 2, 2023, 12 pages.
[cited by applicant]
Bissonnette, Speso, an anti-interleukin-36 receptor antibody, in patients with moderate ro severe atopic dermatitis, JEADV, vol. 10, 2022, 9 pages.
[cited by applicant]
Guenin, Spesolimab use in treatment of pyoderma gangrenosum, JAAD, vol. 10, 2023, 5 pages.
[cited by applicant]
Alavi, Pyoderma Gangroenosum,Am. J. Clin. Dermatol, vol. 18, 2017, 18 pages.
[cited by applicant]
Mrowietz, Spesolimab, an anti-interleukin-36 receptor antibody, Dermatol. Ther., 2020, 15 pages, published online https://doi/org/10.1007/s13555-021-00504-0.
[cited by applicant]
Bachelez, Trial of Spesolimab for Generalized Pustular Psoriasis, New England Journal of Medicine, vol. 385, 2021, p. 2431-2440.
[cited by applicant]
Clinical Trials, A study in patients with Mild or moderate Ulcerative colitis who take a TNF inhibitor, History of changes for study, NCT103123120, Oct. 15, 2021.
[cited by applicant]
International Report on Patentability for PCT/US2022/019742.
[cited by applicant]
Clinical Trials, A study in patients with atopic eczema to test how effective BI 655130 is and how well it is tolerated, 2019; NCT03822832, 87 pages.
[cited by applicant]
Berke, Atopic Dermatitis, Americam Family Physician, vol. 86, 2012, p. 35-42.
[cited by applicant]
Costanzo, Pustular psoriasis with a focus on generalized pustualr psoriasis, Italian J. of Dermatology and Venereology, vol. 157, 2022, p. 489-496.
[cited by applicant]
Puig, Generalized pustular Psoriasis: a global delphi consensus on clinical course, diagnosis, treatment goals, JEADV, vol. 10, 2022, 16 pages.
[cited by applicant]
Alavi, Speso for hidradentitis supparativia, J. Am. Acad Dermatol, vol. 89, 2023, 1 page.
[cited by applicant]
Belato, Response to Interleukin-36 in hidradentitis suurativa, British J. of Dermatology, vol. 176, 2018, 1 page.
[cited by applicant]
Gouin, Trangenic Kallikrein 14 mice display major hair shaft defects associated with desmoglein 3 and 4 degradation, abnormal epidermal differentiation, J. Invest Dermatol., vol. 140, 2020, p. 1184-1194.
[cited by applicant]
Speso entryin IUPHAR/BPS Guide to Phamra, www.guideto[harmacology.org/GRAC/ligandDispalyforward?tab=clinical&ligandld=12169; accessed Jan. 26, 2024.
[cited by applicant]
Hessam, Interleukin-26 in hidradentits suppurativa, Brit. J. Dermatol, vol. 178, 2018, p. 591-592.
[cited by applicant]
Malik, Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature, J. Allergy Clin Immunol., vol. 143, 2019, p. 604-618.
[cited by applicant]
Navarini, Neutrophilic dermatoses and autoinflammatory diseases with skin involvement, Smin Immunopathol, vol. 38, 2016, p. 45-56.
[cited by applicant]
Polesie, Secukinumab in the treatment of generalized pustular psoriasis, acta derm veneral, vol. 97, 2017, p. 124-125.
[cited by applicant]
Tsai, Anti-interleukin and interleukin therapies for psoriasis, Ther. Adv. Muscoloskel. Dis. vol. 9, 2017, p. 277-294.
[cited by applicant]
Kimball, Adalimumab for the treatment of moderate to severe hidradentitis Suppurativa, Annals of internal Medicine, vol. 157, 2012, 19 pages.
[cited by applicant]
Wark, The microbiome in Hidradentitis Supparativa, A review, Dermatol., Thera., vol. 11, 2021, 14 pages.
[cited by applicant]
Zouboulis, Hidradenitis Suppurativa, Dermatology, vol. 231, 2015, p. 184-190.
[cited by applicant]
Revillet, Bacterial Pathogens Associated with Hidradenitis Suppurativa, Emerging Infectious Diseases, vol. 20, 2014, 9 pages.
[cited by applicant]
Frew, The effect of subcutaneous brodalumab on clinical disease activity in hidraenitis suppurativa, J. Am. Acad Derma., vol. 5, 2020, 15 pages.
[cited by applicant]
Glatt, Efficacy and Safety of Bimekizumab in Moderate to severe Hidradenitis Suppurativa, vol. 157, 2021, 10 pages.
[cited by applicant]
Li, Construction strategies for developing expression vectors for recombinant monoclonal antibody production in CHO cells, Molecular Biology Reports, vol. 45, 2018, 6 pages.
[cited by applicant]
Byrd, Neutrophil extracellular traps, B cells, and type 1 interferons contribute to immune dysregulation in hidradenitis suppurativa, Science Translational Med., vol. 508, 2021, 13 pages.
[cited by applicant]
Crommelin, Formulation of Biologics including Biopharmaceutical Considerations, Utrect Institute, vol. 10, 2019, 21 pages.
[cited by applicant]
Flood, Biologic Treatment for Hidradenitis Suppurativa, Am. J. of Clinical Derma., vol. 20, 2019, 14 pages.
[cited by applicant]
Phan, Global prevalence of hidradenitis suppurativa and geograhical variation, Biomedical Derma., vol. 10, 2020, 6 pages.
[cited by applicant]
Zouboulis, Development and validation of the International Hidradenitis Suppurativa severity score system, British J. of Derma., vol. 177, 2017, 9 pages.
[cited by applicant]
Revillet, The microbiological landscape of Anaerobic infections in Hidradenitis Suppurativa, Clinical Infectious Diseases, vol. 65, 2017, 10 pages.
[cited by applicant]
Yellen, Measuring fatigue and other anemia related symptoms with the functional assessment of cancer therapy, J. of Pain and Symptom management, vol. 13, 1997, 12 pages.
[cited by applicant]
Kimball, HiSCR a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa, JEADV, vol. 10, 2016, 6 pages.
[cited by applicant]
Harusato, IL-36y signaling controls the induced regulatory T-cell Th9 cell balance via NFkB activation and STAT transcription factors, Mucosal Immunolgoy, vol. 10, 2017, 13 pages.
[cited by applicant]
Marrakechi, Interleukin-36-Receptor Antagonist Deficieny and Generalized Pustular Psoriasis, The N. E. Journal of Medicine, vol. 365, 2011, 9 pages.
[cited by applicant]
Marrakechi, Inhibition of the Interleukin-36 Pathway for the treatment of Generalized Pustular Psoriasis, The New England Journal of Medicine, vol. 380, 2019, 3 pages.
[cited by applicant]
Taylor, A transgenic mouse tat expresses a diversity of human sequence heavy and light chain immunoglobulins, Nucleic Acids Research, vol. 20, 1992, p. 6287-6295.
[cited by applicant]
Rankin, Case report of hidradenitis suppurativa, SAGE Medical Case reports, vol. 9, 2021, 4 pages.
[cited by applicant]
Cella, Validation of the Functional assessment of chronic illness therapy fatigue scale relative to other instumentation in patients with rheumatoid arthritis, J. of Rheumatology, vol. 32, 2015, 9 pages.
[cited by applicant]
Woodworth, Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II, J. of Rheumatology, vol. 34, 2007, 15 pages.
[cited by applicant]
Moltrasio, Hidradenitis Suppurativa, A perspective on genetic factors involved in the disease, Biomedicines, vol. 10, 2022, 14 pages.
[cited by applicant]
Greenland, Estimation of a common effect parameter from a sparse foll up data, Biometrics, vol. 41, 1985, 15 pages.
[cited by applicant]
Anon, Research Letter, British J. of Derma., vol. 173, 2015, 4 pages.
[cited by applicant]
Krueger, Hidradenitis suppurativa, new insights into disease mechanisms, Br. J. Derma., vol. 190, 2023, 14 pages.
[cited by applicant]
Hessam, Interleukin-36 in hidradenitis suppurativa, evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop, B. Journal of Derma., vol. 178, 2018, 1 page.
[cited by applicant]
Scala, Hidradentitis Suppurativa, Where we are and where we are going, Cells, vol. 10, 2021, 19 pages.
[cited by applicant]
Zouboulis, Hidradenitis Suppurativa Acne Inversa: criteria for diagnosis, Dermatology, vol. 231, 2015, 7 pages.
[cited by applicant]
Costanzo, Pustular Psoriasis wih a focus on generalized pustular psoriasis, Italian J. of Dermatology and Venereaology, vol. 10, 2022, 8 pages.
[cited by applicant]
Puig, Generalized Pustular Psoriasis, A global delphi consensus on clinical course, diagnosis, treatment goals and disease managment, vol. 10, 2022, 16 pages.
[cited by applicant]
Burden, Clinical Disease Measures in Generalized Pustular Psoriasis, American Journal of Clinical Dermatology, 2022, vol. 23, Supp. 1, p. 539-550.
[cited by applicant]
UCB announcement, UCB Announcement Positive Phase 3 studies for Bimekizumab in Hidradenitis Suppurativa, last updated Dec. 2022, 1 page.
[cited by applicant]
Robins, Estimation of a common effect parameter from sparse follow-up data, Biometrics, vol. 51, 1985, p. 55-68.
[cited by applicant]
Highet,
[cited by applicant]
Zouboulis, Development and validation of the International Hidradenitis Suppurativa severity score system, British J. of Derma., vol. 177, 2017, p. 1401-1409.
[cited by applicant]
Calabrese, Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases, Annals of Rheumatic Diseases, vol. 10, 2015, p. 1-12.
[cited by applicant]
Suzuki, Mutations in the g-Secretase Genes NCSTN, PSENEN, and PSEN1 underlie rare forms of Hendradentitis Suppurativa, Journal of Invetigative Dermatology, vol. 132, 2012, p. 2459-2461.
[cited by applicant]
Burden, The Generalized Pustular Psoriasis Physician Global Assessment score, Research Letters, downloaded from https://academic.oupcom/bjd/article/189/1/138/7131301 by guest on May 6, 2024.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2024/018981 mailed Jul. 17, 2024.
[cited by applicant]
Bai, Treatment of Netherton syndrome with spesolimab, JEADV, 2024, vol. 10, p. 1-2.
[cited by applicant]
Brown, Tolerance to Single, but not Multiple, Amino Acid Replacements in Antibody VH CDR2, J. Immunol., 1996, vol. 9, p. 3285-3291.
[cited by applicant]
Bork, Powers and Pitfalls in Sequence Analysis: The 70% Hurdle, Genome Res., 2000, vol. 10, p. 398-400.
[cited by applicant]
Skolnick, From genes to protein structure and function: novel applications of computational approaches in the genomic era, Tibtech, 2000, vol. 18, 6 pages.
[cited by applicant]
Kulmanov, DeepGO: predicting protein functions from sequence and interaction using a deep ontology-aware classifier, Bioinformatics, 2018, vol. 34, p. 660-668.
[cited by applicant]
Ma, “Rapid Response to Spesolimab in a patient with severe refractory pyoderma gangenosum”, Clin. Exp. Dermatol., 2024, vol. 49, p. 82-84.
[cited by applicant]
ClinicalTrials.gov., “A study to test Whether BI 655130 (Spesolimab) prevents Flare-ups in patients with generalized Pustular Psoriasis”, NCT04399837, Dec. 14, 2023, 15 pages.
[cited by applicant]
WHO Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), 2019, vol. 33, No. 1, p. 1-4.
[cited by applicant]
Walpole, The weight of nations: an estimation of adult human Biomass, BVMC Public Health, 2012, vol. 12, p. 1-6.
[cited by applicant]
Bachelez, Trial of Spesolimab for Generalized Pustular Psoriasis, The New England Journal Of Medicine, vol. 385, 2021, No. 26, p. 2431-2440.
[cited by applicant]
Fukaura, Targeting IL-36 in Inflammatory Skin Diseases, BioDrugs, 2023, vol. 37, p. 279-293.
[cited by applicant]
Anaptysbio Reports Harp Phase 2 Top-line Data of Imsidolimab in Moderate-to-severe hidradenitis suppurativa, AnatysBio Reports, Inc., Aug. 31, 2022, p. 1-5.
[cited by applicant]
Khan, Adjustable Locks and Flexible keys, The Journal of immunology, vol. 192, 2014, pp. 5398-5405.
[cited by applicant]
Poosarla, Computational de novo Design of antibodies binding to a peptide with high affinity, Biotechnol. Bioeng., vol. 114, 2017, pp. 1331-1342.
[cited by applicant]
Goel, Plasticity within the antigen-Combining Site may manifest as molecular minicry in the humoral immune response, The Journal of immunology, vol. 173, 2004, pp. 7358-7367.
[cited by applicant]
Vattekatte, Discrete analysis of camelid variable domains, PeerJ, DOI: 10.7717/peerj.8408, eCollection 2020, 28 pages.
[cited by applicant]
Uchiyama, Liquid Formulation for antibody drugs, Biochemica Acta, vol. 1844, No. 11, 2014, pp. 2041-2052.
[cited by applicant]
Daugherty, Formulation and delivery issues for monoclonal Antibody therapeutics, Current trends in Monocl. Antib. Devel. and Manufact., Chapter 8, 2010, pp. 103-129.
[cited by applicant]
Whitaker, A formulation Development Approach to Identify and Select Stable Ultra High Concetration Monoclonal Antibody Formulations with Reduced Viscosities, J. of Pharm. Sci., vol. 106, No. 11, 2017, pp. 3230-3241.
[cited by applicant]